Japan's Takeda Pharmaceutical Co. Ltd. (TKPYY.PK) announced Thursday that new phase 3 data show investigational subcutaneous or SC formulation of Vedolizumab meets primary endpoint in achieving clinical remission at week 52 in patients with moderately to severely active ulcerative colitis.
from RTT - Biotech https://ift.tt/2O3D0OQ
via IFTTT
No comments:
Post a Comment